A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Cabozantinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 18 Mar 2016 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov record.
- 20 Aug 2012 New trial record
- 01 Jul 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.